Xoma/Servier to Develop/Commercialize XOMA 052
Biotech Business 2011, Feb 1, 23, 2
-
- $5.99
-
- $5.99
Publisher Description
XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, and Les Laboratoires Servier (Servier), France's largest privately-held pharmaceutical company, has announced the signing of a regional agreement to jointly develop and commercialize XOMA 052, XOMA's anti-inflammatory drug candidate, in multiple indications. XOMA 052 is designed to inhibit the pro- inflammatory cytokine interleukin-1 beta that is believed to be a primary trigger of pathologic inflammation in multiple diseases. Key elements of this agreement include: -- XOMA will receive approximately $35 million upfront, up to approximately $470 million in milestone payments and tiered royalties up to a mid-teens percentage rate.
More Books Like This
Xoma Reports Net Loss of $13.6 Million for 3rd Qtr 2010 (Financial Report)
2010
Ing Renault F1 Team Chooses Appro Xtreme-X Supercomputer
2008
-2146826259
2011
Novartis Receives US FDA Approval for Zortress (Everolimus) to Prevent Organ Rejection in Adult Kidney Transplant Recipients
2010
YM Biosciences
2008
CMS Expects to Launch CMS024 for the Treatment of Primary Liver Carcinoma Three Years Ahead of Plan in 2013
2011
More Books by Biotech Business
Antidepressants/Cocaine Interact with Brain Cell Targets
2008
Tovaxin Reduces Disability for Multiple Scelerosis (Clinical Report)
2008
Millennium/Harvard Medical School Sign Cancer Research Pact
2008
Alexion's Soliris Gets 2008 Prix Galien USA Award
2008
Chelsea Reports Preliminary Phase III Droxidopa Data (Clinical Report)
2009
Smart Chip System Used to Evaluate Homspera in Wound Healing Studies
2009